Rolston K V, Nguyen H, Amos G, Elting L, Fainstein V, Bodey G P
Department of Medical Specialties, University of Texas M. D. Anderson Cancer Center, Houston 77030.
J Infect Dis. 1994 Feb;169(2):350-5. doi: 10.1093/infdis/169.2.350.
In a prospective, randomized, double-blind study comparing teicoplanin and vancomycin for the treatment of gram-positive bacteremias in neutropenic patients, teicoplanin was given at 6 mg/kg of body weight every 24 h intravenously (i.v.) after initial loading every 12 h for three doses, while vancomycin was administered at 15 mg/kg every 12 h i.v. At enrollment, both groups were comparable in age, sex, underlying hematologic or neoplastic disorder, baseline renal functions, and incidence of neutropenia. Treatment was successful in 19 (90%) of 21 patients who received teicoplanin and 24 (96%) of 25 who received vancomycin (P = .58). Adverse reactions occurred more often in the vancomycin group (31%) than in the teicoplanin group (9%; P = .06) and were primarily cutaneous or gastrointestinal. In conclusion, teicoplanin was better tolerated than vancomycin, and no statistically significant difference in efficacy was detected with the sample size in this study.
在一项比较替考拉宁和万古霉素治疗中性粒细胞减少患者革兰氏阳性菌血症的前瞻性、随机、双盲研究中，替考拉宁在初始负荷剂量每12小时一次共三剂后，每24小时静脉注射6mg/kg体重，而万古霉素每12小时静脉注射15mg/kg。入组时，两组在年龄、性别、潜在血液学或肿瘤性疾病、基线肾功能和中性粒细胞减少发生率方面具有可比性。接受替考拉宁的21例患者中有19例（90%）治疗成功，接受万古霉素的25例患者中有24例（96%）治疗成功（P = 0.58）。万古霉素组不良反应发生率（31%）高于替考拉宁组（9%；P = 0.06），主要为皮肤或胃肠道不良反应。总之，替考拉宁耐受性优于万古霉素，且在本研究样本量下未检测到疗效上的统计学显著差异。
